# US 2021/0172006 A1 · A new inflammation associated, low cell count enterotype

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172006 A1
- Document ID: US20210172006A1
- Status: Published application
- Kind: A1
- Application number: 16/771,856
- Filed: 2018-12-14
- Published: 2021-06-10
- Earliest claimed: 2017-12-15
- Assignees: Vib Vzw; Katholieke Universiteit Leuven, K.U.Leuven R&D; Vrije Universiteit Brussel
- Applicants: Vib Vzw; Katholieke Universiteit Leuven, K.U.Leuven R&D; Vrije Universiteit Brussel
- Inventors: Jeroen Raes; Gwen Falony; Mireia Valles-Colomer; Lindsay Devolder; Gunter Kathagen; Severine Vermeire; Sara Vieira-Silva; João Guedelha Sabino; Marie D'Hooghe; Jacques De Keyser
- Web page: https://patentgrep.com/patent/US20210172006A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 1/701: {Specific hybridization probes}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to the field of inflammation-associated disorders or conditions, more particularly to gut inflammation. Provided herein are means and methods to diagnose and treat or reduce the severity of inflammation-associated disorders or conditions in a subject in need thereof.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating a subject, the method comprising:
quantifying the number of microbial cells in a stool sample from the subject;
determining that the microbiome composition of the stool sample is characterized by low microbial cell count, and by
a high relative fraction of the Bacteroides genus, and/or
a low relative fraction of the Facecalibacterium genus; and
administering an effective amount of anti-inflammatory medication to the subject.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the low microbial cell count is a cell count of less than 1.5×1011 microbial cells per gram of stool.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the high relative fraction of the Bacteroides genus is the Bacteroides genus being among the 25% most abundant genera in the stool sample, and wherein the low relative fraction of the Faecalibacterium genus is the Faecalibacterium genus being among the 25% least abundant genera in the stool sample.

### Claim 5 (depends on 2)

The method according to claim 2, wherein determining that the microbiome composition of the stool sample is characterized by a high relative fraction of the Bacteroides genus and/or a low relative fraction of the Faecalibacterium genus is determined by microbiota phylogenetic profiling.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the phylogenetic profiling is performed using PCR, RT-PCR, qPCR, multiplex PCR, high-throughput sequencing, metatranscriptomic sequencing, identification of strain-specific markers, and/or 16S rRNA analysis.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 2)

The method according to claim 2, wherein the stool sample is further characterized by lower bacterial diversity as compared to a stool sample from a healthy subject.
